期刊文献+

VR1012-TCRγV_1真核表达载体的构建

Construction of eukaryotic expression vector VR1012-TCRγV_1
下载PDF
导出
摘要 目的:构建含TCRγV1基因的重组表达载体。方法:从人淋巴瘤Jurkat细胞中提取总RNA,反转录合成 cDNA克隆入VR1012质粒;转化感受态细菌E.ColiDH5α,以通用引物PCR扩增筛选阳性克隆,并双酶切鉴定;小 量提取质粒进行测序。结果:测序结果证实重组载体中的外源片段序列与GenBank中TCRγV1序列完全相符。结 论:成功构建了含TCRγV1基因的重组表达载体。 Aim: To construct the eukaryotic expression vector VR1012-TCRγV_1. Methods: The total RNA was extracted from human Jurkat cells;followed by a RT step to synthesize cDNA and a PCR amplification.The segment was cloned into VR1012. The recombinant was detected by PCR,endonuclease and sequencing. Results: The sequenced segment in the recombinant perfectly coincided with the selected sequence. Conclusion: The eukaryotic expression vector containing TCRγV_1 gene is constructed successfully.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2005年第2期291-293,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 TCRΓ 真核表达载体 基因疫苗 TCRγ eukaryotic expression vector gene vaccine
  • 相关文献

参考文献6

  • 1张光磊,张彤,陈宗德,张燕齐,阮丽荣,张绍祖.不同载体对癌胚抗原DNA疫苗诱导小鼠产生抗CEA水平的影响[J].中华微生物学和免疫学杂志,1999,19(6):516-518. 被引量:8
  • 2董子明,张义国,杨洪艳,赵明耀,王念慈.对T细胞受体克隆型肽类的免疫应答(英文)[J].河南医科大学学报,1999,34(1):2-7. 被引量:9
  • 3Wong CP, Okada CY, Levy R. TCR vaccines against T cell lymphoma QS-21 and IL-2 adjuvants induce a protective CD8^+ T cell response. J Immunol,1999,162(4) :2 251.
  • 4Ausubel FM,Brent R, Kingston RE, et al. Short protocols in molecular biology. 3th ed. New York:John & Son Inc, 1993.73.
  • 5Hawkins RE, Russell SJ, Marcus R,et al. A pilot study of idiotypic vaccination for follicular b cell lymphoma using a genetic approach. Human Gene Thergpy, 1997,8(10) :1 287.
  • 6Okada CY,Wong CP, Denney DW, et al. TCR vaccines for active immunotherapy of T cell malignancies. J Immunol,1997,159(11) :5 516.

二级参考文献4

  • 1Hwu P,Cancer Res,1995年,55卷,3369页
  • 2Zhang J,Science,1993年,261卷,1451页
  • 3Ulmer J B,Current Opinion Immunology,1996年,8卷,531页
  • 4Klinman D M,Proc Nat Acad Sci USA,1996年,93卷,2879页

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部